Acoustic Neuroma (Vestibular Schwannoma)

While it is not technically classified as a primary brain tumor, it is often managed within the field of brain tumor and neurosurgical care due to its intracranial location and proximity to the brainstem. Understanding the symptoms, causes, and treatment options for acoustic neuroma is essential because, despite its benign nature, the condition can lead to serious complications if left untreated.

What Is an Acoustic Neuroma (Vestibular Schwannoma)?

An acoustic neuroma typically forms within the internal auditory canal before gradually extending into the cerebellopontine angle — the area between the cerebellum and the brainstem. Most tumors grow slowly, often over several years, though growth patterns can vary from patient to patient.

Acoustic neuromas account for around 8% of intracranial tumors and are among the most common peripheral nerve tumors affecting the skull base. In most cases, they occur on only one side and develop sporadically without a known hereditary cause. A small percentage are linked to neurofibromatosis type 2 (NF2), a rare genetic disorder associated with bilateral tumors.

Importantly, acoustic neuroma is not a cancerous ear tumor. It does not spread to other parts of the body or invade surrounding tissue. However, because it develops in a confined area near critical nerves and the brainstem, larger tumors can still become dangerous if untreated. For this reason, acoustic neuromas are commonly managed by multidisciplinary teams involving neurosurgeons, neuro-oncology specialists, and ENT experts.

Acoustic Neuroma Symptoms and Clinical Features

The acoustic neuroma clinical features reflect the anatomy of the structures the tumor compresses as it grows. Symptoms are typically unilateral, gradual in onset, and frequently dismissed or misattributed for months or years before the correct diagnosis is made.

Hearing and Auditory Symptoms

The most common presenting symptom is unilateral sensorineural hearing loss — a progressive reduction in hearing on the affected side that may develop so gradually it goes unnoticed until the deficit is significant. Additional auditory symptoms include:

• Tinnitus on the affected side, typically a high-pitched ringing or hissing, which is sometimes the symptom that first prompts investigation
• A sensation of fullness or pressure in the ear
• The perception of a lump in the ear canal in some cases
• Difficulty understanding speech even when volume appears adequate — a reflection of reduced speech discrimination rather than pure volume loss

Balance and Vestibular Symptoms

Because the tumor arises from the vestibular branch of the vestibulocochlear nerve, balance disturbance is a central feature of acoustic neuroma symptoms. Patients describe a persistent sense of unsteadiness rather than true rotational vertigo — the brain typically compensates gradually for the progressive vestibular loss, which is why acute vertigo attacks are less common than chronic disequilibrium. Patients may report difficulty walking in low light or on uneven surfaces, where visual and proprioceptive cues cannot fully compensate for impaired vestibular input.

Symptoms From Adjacent Nerve and Brainstem Compression

As an acoustic neuroma enlarges beyond the internal auditory canal into the cerebellopontine angle, it comes into proximity with the facial nerve and the trigeminal nerve. Facial numbness — numbness by ear and across the cheek — results from trigeminal nerve compression and is a clinically important sign that the tumor has reached a size requiring active management. Facial weakness, though less common than numbness, indicates facial nerve involvement and warrants urgent assessment.

In larger tumors, acoustic neuroma pressing on the brain stem produces the most serious clinical features:

• Headache from raised intracranial pressure
• Cerebellar ataxia affecting gait and coordination
• Hydrocephalus from compression of CSF pathways in extreme cases

Diagnosing Acoustic Neuroma

Accurate diagnosis of acoustic neuroma requires a combination of imaging, audiological assessment, and clinical evaluation. No single test in isolation provides the complete picture needed for treatment planning. A standard diagnostic workup typically includes:

• Vestibular schwannoma MRI with gadolinium contrast enhancement — the gold standard for diagnosis and treatment planning, providing precise delineation of tumor size, location, and relationship to the facial nerve, brainstem, and cerebellum
• Pure tone audiometry and speech discrimination testing — to document the degree of hearing loss and establish a functional baseline
• Vestibular function testing — to assess the extent of vestibular nerve involvement
• Brainstem auditory evoked response testing — contributing additional diagnostic information in selected cases

MRI identifies tumors at any size, including very small intracanalicular lesions that produce symptoms disproportionate to their volume — making early imaging essential when symptoms are suspicious.

Acoustic Neuroma Treatment: Observation and Medical Management

The three principal approaches to acoustic neuroma treatment are observation with surveillance imaging, stereotactic radiosurgery, and microsurgical resection. The choice between them depends on:

• Tumor size and growth rate on serial imaging
• The patient's age and general medical fitness
• The degree of existing hearing and facial nerve function
• The proximity of the tumor to the brainstem and cochlea
• The patient's informed preferences after thorough discussion of risks and benefits

Small acoustic neuromas in older patients, or tumors that demonstrate no growth on serial MRI over one to two years, are appropriately managed with active surveillance — regular MRI and audiological monitoring without immediate intervention. Many tumors remain stable for extended periods, and deferring treatment avoids procedural risks in patients for whom the balance of risk and benefit does not favour immediate intervention. Surveillance is not passive: any evidence of growth, new symptoms, or deteriorating hearing function triggers reassessment of the treatment plan.

Stereotactic Radiosurgery for Acoustic Neuroma

Stereotactic radiosurgery is the preferred treatment for small to medium acoustic neuromas — typically those measuring less than three centimetres — particularly where useful hearing preservation is a priority or where surgical risk is elevated. It delivers a precisely focused dose of radiation to the tumor without open surgery, halting growth in the majority of cases with tumor control rates exceeding 90 percent at ten years in published series.

Gamma Knife and CyberKnife Treatment

Two principal radiosurgical platforms are used for acoustic neuroma: Gamma Knife and CyberKnife. Gamma Knife uses 192 cobalt-60 sources to deliver convergent beams with sub-millimetre accuracy to intracranial targets and has the most extensive published evidence base for vestibular schwannoma treatment. CyberKnife is a robotic linear accelerator system that delivers treatment with comparable precision and offers the flexibility of hypofractionated treatment — dividing the dose across three to five sessions — which may reduce the risk of radiation-related complications in tumors adjacent to critical structures such as the cochlea and facial nerve.

Radiosurgery does not remove the tumor — it arrests its growth — and patients require long-term MRI follow-up to confirm durable control. In a minority of cases, tumors continue to grow despite radiosurgery and require surgical salvage, which is why lifelong radiological surveillance remains mandatory regardless of initial treatment response.

Acoustic Neuroma Surgery (Microsurgical Resection)

Acoustic neuroma surgery — microsurgical resection — remains the definitive treatment for large tumors, rapidly growing lesions, tumors causing brainstem compression, and cases where tissue diagnosis is required. Three surgical approaches are used depending on tumor size, location, and the status of residual hearing:

• Retrosigmoid approach — provides access to the cerebellopontine angle and internal auditory canal with the possibility of hearing preservation in selected cases
• Translabyrinthine approach — sacrifices residual hearing but provides the widest access to the internal auditory canal and the most direct facial nerve identification
• Middle fossa approach — used for small intracanalicular tumors where hearing preservation is the primary surgical objective

Facial nerve preservation is a central goal of acoustic neuroma surgery regardless of approach. In experienced hands, anatomical preservation of the facial nerve is achieved in the large majority of cases, though functional outcomes depend on the degree of nerve involvement by tumor. Intraoperative facial nerve monitoring is standard practice at specialist centres and provides real-time feedback throughout the resection.

Acoustic Neuroma Surgery Recovery

Acoustic neuroma surgery recovery varies with the surgical approach and tumor size. Hospital stay typically ranges from three to seven days. Fatigue, headache, and balance disturbance are expected in the early postoperative weeks as the brain adapts to altered vestibular input. Most patients return to light activity within four to six weeks, with full recovery taking three to six months. Vestibular rehabilitation physiotherapy significantly accelerates balance recovery and is a standard component of postoperative care at centres with dedicated acoustic neuroma programmes.

Acoustic Neuroma Life Expectancy and Treatment Success Rates

Acoustic neuroma life expectancy is not reduced by the condition itself in the great majority of patients. Because these tumors are benign and do not metastasise, successful treatment — whether by radiosurgery or microsurgical resection — is associated with normal long-term survival, and the condition is not considered life-threatening in the absence of brainstem compression.

Treatment success rates are favourable across both modalities. Stereotactic radiosurgery achieves durable tumor control in approximately 90 to 95 percent of appropriately selected patients at ten years, with facial nerve preservation rates exceeding 95 percent at experienced centres. Microsurgical resection achieves gross total removal in the majority of cases with recurrence rates below five percent, and comparable facial nerve preservation rates in specialist hands — though functional nerve recovery may take months and is not guaranteed where tumor involvement is significant. Hearing preservation remains the least predictable outcome with either approach and depends heavily on preoperative function, tumor size, and technique.

The principal long-term considerations following treatment are residual hearing, facial nerve function, vestibular adaptation, and in a minority of cases, recurrence requiring further intervention — all monitored through structured audiological and radiological follow-up.

Neurosurgery and Oncology Treatment in Turkey

Turkey has established itself as a destination of genuine clinical substance for patients seeking neurosurgical and oncology care, combining internationally trained specialist teams, current-generation technology, and treatment costs that are a fraction of those in Western Europe or North America. Istanbul in particular hosts several JCI-accredited hospital groups with dedicated neurosurgery and skull base surgery programmes, stereotactic radiosurgery platforms including Gamma Knife and CyberKnife, and the case volumes that underpin surgical expertise. For patients with acoustic neuroma requiring either radiosurgical or microsurgical treatment, Turkey offers access to the full spectrum of management options within a single integrated care environment.

The breadth of neurosurgical and oncological capability available in Turkey's leading private hospital networks extends well beyond acoustic neuroma. Brain tumor surgery, spinal neurosurgery, functional neurosurgery, and radiation oncology — including SBRT and stereotactic radiosurgery for both intracranial and extracranial indications — are delivered at standards that meet or exceed those of equivalent European centres, with the added advantage of substantially shorter waiting times and greater scheduling flexibility for international patients.

Peripheral Nerve Surgery at Medical Park Hospitals

Medical Park Hospitals provides specialist management of acoustic neuroma and the broader category of peripheral nerve tumors through dedicated neurosurgery and skull base surgery teams operating across its Istanbul hospital network. Surgical treatment of vestibular schwannoma is supported by intraoperative neurophysiological monitoring — including continuous facial nerve monitoring — to maximise the probability of nerve preservation during tumor resection. Stereotactic radiosurgery for acoustic neuroma is available through Medical Park's Gamma Knife and CyberKnife platforms, allowing patients to receive either surgical or radiosurgical treatment — or a combination of both in recurrent or residual disease — within the same hospital group.

Beyond acoustic neuroma, Medical Park's peripheral nerve surgery programme encompasses the diagnosis and surgical management of schwannomas, neurofibromas, and malignant peripheral nerve sheath tumors at all anatomical locations, as well as nerve reconstruction procedures for patients with treatment-related or traumatic nerve injury. Multidisciplinary tumor board review ensures that every patient with a peripheral nerve tumor receives a treatment plan informed by the collective expertise of neurosurgery, oncology, radiology, and neuropathology before any intervention begins.

For patients seeking advanced diagnosis and treatment options for acoustic neuroma and other complex neurological conditions, further information about comprehensive neurosurgical care can be found in our  guide on Brain Tumor Surgery in Turkey.